Wuhan YZY Biopharma Co Ltd

The malignant pleural effusion market is projected to register incremental growth at a compound annual growth rate of 4.9% during the forecast period from 2026 to 2036, according to a new report from DelveInsight. The market size across the seven major markets—the United States, the EU4 countries of Germany, France, Italy, and Spain, the United Kingdom, and Japan—was estimated at USD 2 billion in 2025, with the United States accounting for the largest share. The total number of incident cases of malignant pleural effusion in the seven major markets is approximately 480,000 in 2025. Growth is expected to be driven by the rising incidence of metastatic cancers, improved diagnostic techniques, and the anticipated launch of emerging therapies such as PTS500 from Gongwing Biopharm, M701 from Wuhan YZY Biopharma, and RSO-021 from RS Oncology. These pipeline candidates are currently in clinical trials and are poised to transform the treatment landscape, which today relies heavily on palliative drainage-based interventions.